Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin with or without Nivolumab in CD30+ Lymphoma
NCT01703949Phase 2Active, not recruiting
- Sponsor
- University of Washington
- Start
- Mar 2013
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), sponsored by University of Washington. Started Mar 2013; status: active, not recruiting.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01703949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01703949.